Hormonal therapy and chemotherapy of renal-cell carcinoma

Seminars in Oncology

Volumn 10, Issue 4, 1983, Pages 422-430

  Harris, David T ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BLEOMYCIN; BUTYLNITROSOUREA; CARMUSTINE; CISPLATIN; CORTISONE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DIMETHYLNITROSAMINE; ESTRADIOL; ESTRAMUSTINE; FLUOROURACIL; FLUOXYMESTERONE; HYDROXYPROGESTERONE CAPROATE; HYDROXYUREA; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; MITOGUAZONE; NAFOXIDINE; PREDNISONE; PROGESTERONE; SEMUSTINE; TAMOXIFEN; TESTOSTERONE PROPIONATE; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; DRUG RECEPTOR BINDING; DRUG THERAPY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY CARCINOMA; NORPROGESTERONE CAPROATE; PHARMACOKINETICS; THERAPY;

ADENOCARCINOMA; ANIMAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPARATIVE STUDY; ESTROGEN ANTAGONISTS; HAMSTERS; HORMONES; HUMAN; KIDNEY NEOPLASMS; MICE; PROGESTERONE; RECEPTORS, CELL SURFACE; TESTOSTERONE;

EID: 0021013543     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. Cancer of the kidney—Natural history and staging
2. Renal cell carcinoma: Natural history and results of treatment
3. Diagnosis and management of renal cell carcinoma
4. Kidney damage in golden hamster following chronic administration of diethylstilboesterol and sesame oil
5. Estrogen-induced tumors of the kidney I Incidence of renal tumors in intact and gonadectomized male golden hamsters treated with diethylstilbestrol
6. Estrogen-induced tumors of the kidney. II. Effect of dose, administration, type of estrogen and age on the induction of renal tumors in intact male golden hamsters
7. Observations on hormone-dependent renal tumors in the golden hamster
8. Endocrine factors involved in the induction, prevention, and transplantation of kidney tumors in the male golden hamster
9. Estrogen-induced tumors of the kidney
10. I. The oestrogen-induced renal tumor of the Syrian hamster. Hormone treatment and possible relationship to carcinoma of the kidney in man
11. II. Effect of endocrine ablation procedures on the transplanted oestrogeninduced tumor of the Syrian hamster
12. Sex hormones and renal neoplasia: Inhibition of tumor of hamster kidney by an estrogen antagonist, an agent of possible therapeutic value in man
13. Incidence of mammary and pituitary tumors in hybrid mice treated with stilbestrol
14. The inhibition of dimethylnitrosamine-induced renal tumorigenesis in NZO/Bl mice by orchiectomy
15. Influence of sex hormones on kidney tumors induced in rats with N-butylnitrosourea
16. Current status of the therapy of advanced renal carcinoma
17. Medroxyprogesterone acetate (Provera) in treatment of metastatic renal cancer
18. The use of progestogen in the treatment of metastatic carcinoma of the kidney and uterine body
19. Treatment of metastatic renal cell carcinoma
20. Renal Cell carcinoma: An analysis of 31 cases with assessment of endocrine therapy
21. Phase II study of nafoxidine in the therapy for advanced renal carcinoma
22. Treatment of renal carcinoma: A phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine
23. Phase II study of tamoxifen in patients with advanced renal cell carcinoma
24. Study of tamoxifen in metastatic renal cell carcinoma and the influence of certain prognostic factors: A Southwest Oncology Group study
25. Tamoxifen in unresectable hypernephroma
26. High-dose tamoxifen in metastatic renal cell carcinoma
27. A phase II evaluation of bacillus Calmette-Guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma
28. Hormonal therapy in advanced renal cell carcinoma
29. Hormonal therapy of renal carcinoma alone and in association with cytostatic drugs
30. Methyl CCNU, Velban, and depo-Provera treatment trials in advanced renal cancer
31. Chemotherapy of adenocarcinoma of the kidney
32. The role of adjunctive renal cell carcinoma
33. Hormonal treatment of metastases of renal carcinoma
34. Human renal cell carcinoma as a hormone-dependent tumor
35. Hormone receptors in renal cell carcinoma
36. Clinical aspects of steroid hormone receptors in human renal cell carcinoma
37. The current status of chemotherapy for advanced renal cell carcinoma
38. Treatment of metastatic hypernephroma
39. The chemotherapy of urologic cancer
40. Renal cell carcinoma: Natural history and chemotherapeutic experience
41. Non-hormonal chemotherapy for disseminated renal cell carcinoma
42. Current status of chemotherapy in metastatic renal carcinoma
43. Treatment of advanced renal cell carcinoma
44. Current therapy for renal cell carcinoma
45. Current status of chemotherapy, hormonal therapy and immunotherapy in the treatment of renal cell carcinoma
46. Treatment of advanced renal cell carcinoma—Traditional methods and innovative approaches
47. Clinical trial of cisplatinum in metastatic renal cell carcinoma
48. Methyl-glyoxal bis-guanylhydrazone (methyl GAG, MGBG) in advanced human malignancy
49. Phase I–II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma
50. A phase II trial of methyl-glyoxal bis-guanylhydiazone in renal carcinoma
51. Phase II trial of methyl-GAG in advanced renal cancer
52. Continuous preoperative intra-arterial perfusion of renal tumors with chemotherapeutic agents
53. Cancer chemotherapy, continuous intra-arterial infusion
54. Combined intra-arterial actinomycin D and radiation therapy for surgically unresectable hypernephroma
55. Metastatic kidney cancer treated with multiple drug therapy at the Rotterdam Radiotherapy Institute
56. CCNU, bleomycin, methyl prednisolone with or without adriamycin in renal cell carcinoma. A randomized trial
57. Chemotherapy of advanced renal cell carcinoma with vinblastine and CCNU
58. Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine
59. Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate
60. Estramustine phosphate (Emcyt) as treatment for metastatic renal carcinoma
61. Combined therapy of advanced hypernephroma with medroxyprogesterone, BCG, adriamycin, and vincristine
62. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs
63. Soft agar clonogenic assay for primary human renal carcinoma: In vitro chemotherapeutic drug sensitivity testing
64. In vitro chemotherapeutic testing of urologic tumors
65. Medroxyprogesterone acetate in treatment of renal cell carcinoma
66. Hormonal therapy of renal cancer
67. Hormones in the treatment of metastatic renal cancer
68. Androgens in metastatic renal adenocarcinoma
69. Yoshi 864 plus medroxyprogesterone acetate in adenocarcinoma of the kidney: A Southwest Oncology Group study
70. Single agent therapy for renal cell carcinoma: CCNU, vinblastine, thiotepa or bleomycin
71. Yoshi 864 (1-propanol, 3,3′-iminodi-dimethanesulfonate [ester], hydrochloride): A phase II study in solid tumors
72. Phase II evaluation of chlorozotocin in patients with renal cell carcinoma
73. High dose cyclophosphamide in metastatic renal cell cancer
74. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without radiation
75. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma
76. Clinical experience with mitomycin C
77. Dose response evaluation of adriamycin in human neoplasia
78. Clinical trial of bleomycin in the treatment of metastatic renal carcinoma
79. Phase II evaluation of bleomycin
80. Phase I study of 4′-epi-adriamycin
81. Phase II study of 4′-epi-doxorubicinin metastatic renal cancer
82. Phase I evaluation of N-trifluoroacetyladriamycin-14-valerate (AD 32), an adriamycin (A) analog
83. Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer
84. Further clinical evaluation of 2′ deoxy-5-fluorouridine
85. 6-mercaptopurine given intravenously at weekly intervals to patients with advanced cancer
86. Phase II trial with high-dose methotrexate therapy and citrovorum factor rescue
87. Methotrexate-citrovorum factor used alone and in combination chemotherapy for advanced hypernephromas
88. 6-thioguanine: A phase I study of intermittent oral and intravenous therapy in solid tumors
89. Renal cell carcinoma: A preliminary clinical trial of methodichlorophen (DDMP)
90. Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma
91. Phase II trial of vindesine in advanced metastatic cancer
92. L-asparaginase: A new type of anticancer drug
93. Clinical study of tetramezylmannitol in neoplastic diseases
94. A phase II trial of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with renal cell carcinoma and refractory small cell carcinoma of the lung
95. Phase II trial of 4′-(9-acridinylamino) methane-sulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma
96. Methyl-glyoxal bis-guanylhydrazone (methyl GAG, MGBG) in advanced renal carcinoma
97. An EORTC phase II study of methyl-glyoxal bis-guanylhydrazone in advanced renal cell cancer
98. Chemotherapy with hydroxyurea in renal cell carcinoma
99. Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: A Southwest Oncology Group study
100. Piperazinedione in metastatic renal carcinoma
101. Phase II trial of bisantrene for advanced hypernephroma
102. Clinical results with a chemotherapeutic association in the treatment of 70 epithelial tumor cases
103. Adriamycin studies in adult patients
104. Combination vincristine and hydroxyurea for metastatic renal carcinoma
105. Combination chemotherapy with adriamycin for solid tumors: A phase II trial
106. Immunotherapy of metastatic renal cell carcinoma
107. Chemotherapy of metastatic renal adenocarcinoma with a five-drug regimen
108. A comparative trial of the combination vinblastine, methotrexate, and bleomycin with and without tamoxifen for metastatic renal cell carcinoma
109. Vinblastine cyclophosphamide and 5-fluorouracil combination chemotherapy for metastatic hypernephroma
110. Combination chemoimmuno therapy for advanced renal carcinoma with adriamycin, bleomycin, vincristine, cyclophosphamide, plus BCG
111. Combination of vinblastine and bleomycin in metastatic renal cell carcinoma
112. Phase II trial of combination methyl-GAG and vinblastine in the treatment of metastatic renal carcinoma